Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ECYT > SEC Filings for ECYT > Form 8-K on 25-Mar-2014All Recent SEC Filings

Show all filings for ENDOCYTE INC

Form 8-K for ENDOCYTE INC


25-Mar-2014

Termination of a Material Definitive Agreement, Other Events, Financial Statements a


Item 1.02 Termination of a Material Definitive Agreement.

On December 20, 2013, Endocyte, Inc. (the "Company") entered into a Sales Agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen") to offer and sell shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), with an aggregate offering price of up to $60,000,000 from time to time through Cowen as its sales agent. The offer and sale of Common Stock under the Sales Agreement would have been made pursuant to the Company's registration statement on Form S-3 (File No. 333-187334) (the "Prior Registration Statement"). A summary of the material terms and conditions of the Sales Agreement and a copy of the Sales Agreement are set forth in the Company's Current Report on Form 8-K filed on December 23, 2013, which is incorporated herein by reference.

Effective March 25, 2014, the Company terminated the Sales Agreement. No shares had been issued or sold under the Sales Agreement prior to its termination. The Company has filed a new shelf registration statement on Form S-3 on March 25, 2014, which became effective upon filing, and has also filed a post-effective amendment to the Prior Registration Statement, deregistering the securities issuable thereunder.



Item 8.01 Other Events.

On March 21, 2014, Endocyte, Inc. (the "Company") issued a press release, along with Merck, announcing that positive opinions were received from the Committee for Medicinal Products for Human Use of the European Medicines Agency for VYNFINIT® (vintafolide) and companion imaging agents FOLCEPRI®(etarfolatide) and NEOCEPRI® (Intravenous (IV) folic acid) in patients with platinum-resistant ovarian cancer. A copy of the press release is attached to this Current Report as Exhibit 99.1 and is incorporated herein by reference.

On March 21, 2014, the Company issued a press release to announce the Phase 2b TARGET trial results evaluating vintafolide/docetaxel combination in non-small cell lung cancer. A copy of the press release is attached to this Current Report as Exhibit 99.2 and is incorporated herein by reference.



Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press release dated March 21, 2014

99.2 Press release dated March 21, 2014

  Add ECYT to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ECYT - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.